TABLE 2.
Univariate and multivariate analysis of progression‐free survival and overall survival in all patients (n = 77)
| Variable | Progression‐free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||
| P value | HR (95% CI) | P value | P value | HR (95% CI) | P value | |
| Age | ||||||
| ≤65 years versus > 65 years | .590 | 1.110 (0.578‐2.131) | .755 | .828 | 1.029 (0.421‐2.514) | .950 |
| Gender | ||||||
| Male versus female | .479 | 0.700 (0.342‐1.433) | .330 | .803 | 0.909 (0.383‐2.160) | .830 |
| Smoking status | ||||||
| Never versus ever/current | .639 | 1.202 (0.497‐2.909) | .683 | .806 | 1.106 (0.345‐3.547) | .865 |
| Stage | ||||||
| IIIB‐IIIC versus IVA‐IVB | .783 | 1.051 (0.425‐2.600) | .914 | .637 | 0.968 (0.278‐3.368) | .959 |
| Brain metastases | ||||||
| No versus yes | .012 | 0.261 (0.132‐0.515) | <.001 | .002 | 0.313 (0.145‐0.673) | .003 |
| First‐line treatment | ||||||
| Crizotinib versus platinum‐pemetrexed | <.001 | 0.199 (0.105‐0.378) | <.001 | .176 | 0.565 (0.269‐1.189) | .133 |
Abbreviations: CI, confidence interval; HR, hazard ratio.